Enliven Therapeutics, Inc.ELVNNASDAQ
Loading
Other Income/Expenses (Net) Over TimeStrong
Percentile Rank100
3Y CAGR+141.8%
Studio
Year-over-Year Change

Net other income and expenses outside core operations

3Y CAGR
+141.8%/yr
Annual compound
Percentile
P100
Near historical high
vs 3Y Ago
14.1x
Strong expansion
Streak
5 yr
Consecutive growthStrong
PeriodValueYoY Change
TTM$15.96M+1.3%
2024$15.76M+32.0%
2023$11.95M+958.0%
2022$1.13M+5031.8%
2021$22000.00+100.2%
2020$-9.65M-1577.5%
2019$653000.00+198.9%
2018$-660000.00-107.2%
2017$9.13M-